Aetna, a CVS Health company, announced the State of Michigan has recommended the company for a new contract to serve MI Coordinated Health beneficiaries who are eligible for both Medicare and Medicaid. Aetna was selected as part of a competitive bidding process. Under the new contract, eligible Michigan residents will have access to an Aetna Highly Integrated Dual Eligible Special Needs Plan, which provides all Medicare benefits, most Medicaid covered benefits and integrates long-term services and supports for beneficiaries. Aetna will continue supporting dually eligible Michigan members in the 10 counties it currently serves and expand services to an additional 29 counties in 2027. Aetna has been serving dually eligible beneficiaries in Michigan through a Medicare-Medicaid Plan for over 10 years and currently manages the health benefits of approximately 8,500 dually eligible members. The contract award is part of the State’s transition from an MMP plan design, which was in place as a demonstration program. Pending the completion of the state’s protest period and readiness review, the new contract is expected to begin on January 1, 2026, and end on December 31, 2033, with the option of renewals. This contract has no impact on the existing contract with Aetna Better Health of Michigan to serve the Medicaid-eligible population through the state’s Comprehensive Health Care Program.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Humana star shortfall largest in managed care, says Morgan Stanley
- Election 2024: Where To Put Your Money Ahead of the Vote
- CVS Health price target raised to $76 from $66 at Truist
- Humana down after CMS posts Medicare Part C and D performance data
- Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls